Tocilizumab, on the other hand, targets a single component of the cytokine storm associated with COVID-19 (IL-6), and although studies confirmed the involvement of IL-6, the clinical benefits of targeting IL-6 to mitigate the cytokine storm, as well as of immunosuppression in general in COVID-19 patients, is not well understood [101]. The gene discussed is IL6; the disease is COVID-19.